Tonje A. Aksnes, MD1, Trygve B. Tjugen, MD1, Roland E. Schmieder, MD, PhD2, Sverre E. Kjeldsen, MD, PhD1,3, Stevo Julius, MD, ScD3

Patients with new-onset diabetes mellitus in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial had an increased incidence of atrial fibrillation compared with patients without diabetes. Clustering of risk factors or the presence of dysglycemia may make the heart more susceptible to arrhythmias.